Evidence map›Paper›PMID 31988102›Full record

Trial reportAntimicrobial agents and chemotherapy2020

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.

Andreas H Diacon, Veronique R De Jager, Rodney Dawson, Kim Narunsky, Naadira Vanker, Divan A Burger, Daniel Everitt, Frances Pappas, Jerry Nedelman, Carl M Mendel

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06590428 (Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06590428 narecruitingnot on this mapstarted 2026, after this paper: background citation

Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2026 to 2029Enrolled280ConditionsRifampin-resistant Tuberculosis, Drug-resistant TuberculosisArmsTherapeutic Drug Monitoring for Linezolid
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  4. Trial
  5. Article
  6. Review
  7. [Perinatal tuberculosis presenting as endobronchial tuberculosis diagnosed by bronchoscopy: a case report].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Andreas H DiaconDivision of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa ahd@sun.ac.za.
Veronique R De JagerTask Applied Science, Bellville, South Africa.
Rodney DawsonDivision of Pulmonology, Department of Medicine, Groote Schuur Hospital and University of Cape Town Lung Institute, Cape Town, South Africa.
Kim NarunskyDivision of Pulmonology, Department of Medicine, Groote Schuur Hospital and University of Cape Town Lung Institute, Cape Town, South Africa.
Naadira VankerTask Laboratory, Parow, South Africa.
Divan A BurgerDepartment of Statistics, University of Pretoria, Pretoria, South Africa.
Daniel EverittTB Alliance, New York, New York, USA.
Frances PappasTB Alliance, New York, New York, USA.
Jerry NedelmanTB Alliance, New York, New York, USA.
Carl M MendelTB Alliance, New York, New York, USA.
TB Alliance · USTask Applied Science · ZAGroote Schuur Hospital · ZAUniversity of Cape Town · ZAUniversity of Pretoria · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents, but the most effective dosing strategy is yet unknown. From November 2014 to November 2016, we randomized 114 drug-sensitive treatment-naive pulmonary tuberculosis patients from Cape Town, South Africa, to one of six 14-day treatment arms containing linezolid at 300 mg once daily (QD), 300 mg twice daily (BD), 600 mg QD, 600 mg BD, 1,200 mg QD, 1,200 mg three times per week (TIW), or a combination of isoniazid, rifampin, pyrazinamide, and ethambutol. Sixteen-hour sputum samples were collected overnight, and bactericidal activity was characterized by the daily percentage change in time to positivity (TTP) and the daily rate of change in log

Indexed as

AdultAntitubercular AgentsDrug Therapy, CombinationEthambutolFemaleHumansIsoniazidLinezolidMaleMicrobial Sensitivity TestsMycobacterium tuberculosisPyrazinamideRifampinSouth AfricaSputumTuberculosis, PulmonaryAntitubercular AgentsEthambutolIsoniazidLinezolidPyrazinamideRifampinbactericidal activitylinezolidMycobacterium tuberculosis

Identifiers

PMID31988102
PMCPMC7179319
OpenAlexW3001687693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.